Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20595101 | 0.84 | CA12 (0.49) | CA12CA1CA2CA9TP53 | |
| SCHEMBL21990144 | 0.83 | LMNA (0.69) | CA12CA1CA2CA9TP53 | |
| SCHEMBL21990025 | 0.81 | STING1 (0.69) | CA12CA1CA2CA9TP53 | |
| SCHEMBL21606323 | 0.81 | SMN1; SMN2 (0.52) | TP53SMN1; SMN2MAPTTSHRLMNA | |
| SCHEMBL21905562 | 0.80 | SMN1; SMN2 (0.51) | TP53SMN1; SMN2MAPTTSHRLMNA | |
| SCHEMBL21606302 | 0.80 | STING1 (0.51) | TP53SMN1; SMN2MAPTTSHRLMNA | |
| SCHEMBL21932342 | 0.80 | STING1 (0.72) | TP53SMN1; SMN2MAPTTSHRLMNA | |
| SCHEMBL21932446 | 0.80 | STING1 (0.72) | TP53SMN1; SMN2MAPTTSHRLMNA | |
| SCHEMBL22000894 | 0.80 | STING1 (0.72) | TP53SMN1; SMN2MAPTTSHRLMNA | |
| SCHEMBL31065605 | 0.80 | STING1 (0.72) | TP53SMN1; SMN2MAPTTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172483-A1 | HETEROCYCLIC SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| US-20200172483-A1 | HETEROCYCLIC SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172483-A1 | HETEROCYCLIC SMALL MOLECULE MODULATORS OF HUMAN STING | STING1, IRF3, CGAS | CA12 4819/4885CA1 4880/4885CA2 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.